Geron Corporation (GERN) Fundamentals

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug.
SHARE INFORMATION
Market Cap$ 498,230,181
Shares Outstanding377,447,107
Float375,167,339
Percent Float99.4%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 1,393,000
Latest Fiscal EPS$ -0.35
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions287
Institutional Holdings Date2022-04-30
Institutional Bought Previous 3 Months5,274,901
Institutional Holdings Percent65.0%
Institutional Sold Previous 3 Months11,346,602
Insider Holdings Date2022-03-31
Insider Bought Previous 3 Months5,855,891
Insider Holdings Percent1.5
Insider Sold Previous 3 Months-
Insider Shares Owned4,961,798
TRADING INFO
52 Week High$ 2.23
52 Week Low$ 0.99
52 Week High Change$ -6.38
21 Day Moving Average$ 1.4214
21 Day Extended Moving Average$ 1.4042
50 Day Moving Average$ 1.3824
50 Day Extended Moving Average$ 1.3709
200 Day Moving Average$ 1.3241
200 Day Extended Moving Average$ 1.3465
10 Day Average Volume2,928,674
20 Day Average Volume2,420,662
30 Day Average Volume2,332,577
50 Day Average Volume2,716,759
Alpha0.004898
Beta0.9830
Standard Deviation0.219663
R20.044869
7 Day Price Change$ -0.11
7 Day Percent Change-7.69%
21 Day Price Change$ -0.16
21 Day Percent Change-10.81%
30 Day Price Change$ -0.18
30 Day Percent Change-12.0%
Month to Date Price Change$ -0.09
Month to Date Percent Change-6.38%
Quarter to Date Price Change$ -0.04
Quarter to Date Percent Change-2.94%
180 Day Price Change$ -0.22
180 Day Percent Change-14.29%
200 Day Price Change$ -0.22
200 Day Percent Change-14.29%
Year to Date Price Change$ 0.10
Year to Date Percent Change8.2%

Geron Corporation (GERN) Key Ratios

PROFITABILITY
EBIT Margin-8,260.3%
EBITDA Margin-8,202.2%
Pre-Tax Profit Margin-10,604.8%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 1,379,000
Revenue Per Share$ 0.0037
Revenue (3 Years)$ 21.47
Revenue (5 Years)$ -22.48
FINANCIAL STRENGTH
Price to Tangible Book5.00
Total Debt To Equity0.60
Int Coverage-25.40
Current Ratio3.80
Leverage Ratio1.60
Quick Ratio3.70
Long Term Debt To Capital0.36
VALUATION MEASURES
PE Ratio-3.70
Enterprise Value$ 379,222,239
Price to Sales361.2982
Price to Free Cash-5.10
PE High Last 5 Years-6.70
Price To Book5.00
Price To Cash Flow41.10
PE Low Last 5 Years-9.20
Price to Tangible Book5.00
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.50
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-53.49
Return on Equity-82.37
Return on Capital-59.63

Geron Corporation (GERN) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEOJohn A. Scarlett
Emplyoees72
Last AuditUQ
CIK0000886744
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address919 East Hillsdale Boulevard
Suite 250
Foster City, CA 94404
Websitehttps://www.geron.com
Facsimile+1 650 473-7700
Telephone+1 650 473-7700
Emailinvestor@geron.com


Your Recent History
NASDAQ
GERN
Geron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.